Leading Executives in Drugs and Pharmaceuticals
Albert Bourla
Chairman & Chief Executive Officer, Pfizer
Led Pfizer through development and global rollout of the first authorized mRNA COVID-19 vaccine and continues to steer a broad pipeline in oncology and vaccines.
Company bio | LinkedIn | X (Twitter)
Robert M. Davis
Chairman & Chief Executive Officer, Merck & Co. (MSD)
Succeeded Ken Frazier and now leads Merck’s global strategy across human health, vaccines and animal health, building on the company’s immuno‑oncology leadership.
Company bio | LinkedIn | Company X
Joaquin Duato
Chairman & Chief Executive Officer, Johnson & Johnson
Chaired and led J&J’s pivot to focus on Innovative Medicine and MedTech following the Kenvue separation.
Company bio | Media relations | Company LinkedIn
Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Novartis
Physician‑CEO credited with transforming Novartis into a focused innovative medicines company and advancing next‑gen platforms like radioligand and cell & gene therapies.
Company bio | LinkedIn | Company X
Thomas Schinecker, Ph.D.
Chief Executive Officer, Roche Group
Former Diagnostics head elevated to Group CEO in 2023, guiding Roche’s combined Pharma and Diagnostics innovation engine.
Company bio | LinkedIn | Company X
Paul Hudson
Chief Executive Officer, Sanofi
Leads Sanofi’s modernization agenda and pipeline focus on breakthrough medicines and vaccines, with emphasis on impact at scale.
Company bio | LinkedIn | Company X
Dame Emma Walmsley, DBE
Chief Executive Officer, GSK
At the helm since 2017, she has sharpened GSK’s R&D focus and expanded its vaccines leadership.
Company bio | Company LinkedIn | Company X
Sir Pascal Soriot
Chief Executive Officer, AstraZeneca
Longest‑serving Big Pharma CEO (since 2012), he steered AZ through the pandemic while accelerating growth in oncology and biopharma.
Company bio | Company LinkedIn | Company X
David A. (Dave) Ricks
Chair & Chief Executive Officer, Eli Lilly and Company
CEO since 2017 who has overseen record R&D output and strong growth across diabetes, obesity and neuroscience portfolios.
Company bio | LinkedIn | Company X
Chris Boerner, Ph.D.
Board Chair & Chief Executive Officer, Bristol Myers Squibb
Commercial strategist turned chief who became CEO in November 2023 and board chair in 2024, now driving BMS’s next phase of innovation.
Company bio | Company LinkedIn | Company X
Robert A. Michael
Chairman of the Board & Chief Executive Officer, AbbVie
Took the helm in 2024 and was named chairman in 2025, charged with extending AbbVie’s growth beyond Humira with a diversified portfolio.
Company bio | Company LinkedIn | Company X
Robert A. Bradway
Chairman & Chief Executive Officer, Amgen
At Amgen’s helm since 2012, he’s led the biotech’s expansion in biologics and strategic deals.
Company bio | Company LinkedIn | Company X
Christopher A. Viehbacher
President & Chief Executive Officer, Biogen
Veteran pharma leader appointed in 2022 to re‑energize Biogen’s neuroscience pipeline and portfolio.
Company bio | Company LinkedIn | Company X
Daniel O’Day
Chairman & Chief Executive Officer, Gilead Sciences
Former Roche executive leading Gilead since 2019, guiding its HIV/viral leadership and oncology expansion.
Company bio | Company LinkedIn | Company X
Lars Fruergaard Jørgensen
President & Chief Executive Officer, Novo Nordisk
CEO since 2017 overseeing the company’s global leadership in diabetes and metabolic disease.
Company bio | Company LinkedIn | Company X
Christophe Weber
President, Chief Executive Officer & Representative Director, Takeda Pharmaceutical Company
Globalized and transformed Takeda’s R&D footprint since becoming CEO in 2015; successor named for 2026 as part of long‑term planning.
Company bio | Company LinkedIn | Company X
Stéphane Bancel
Chief Executive Officer, Moderna
Long‑time CEO who helped pioneer mRNA medicines and led Moderna’s COVID‑19 vaccine program.
Company bio | LinkedIn | Company X
Ugur Sahin, M.D.
Co‑founder & Chief Executive Officer, BioNTech
Physician‑scientist and co‑founder who led BioNTech’s Project Lightspeed and co‑developed the first authorized mRNA COVID‑19 vaccine.
Company bio | Company LinkedIn | Company X
Leonard S. Schleifer, M.D., Ph.D.
Board Co‑Chair, President & Chief Executive Officer, Regeneron Pharmaceuticals
Company co‑founder who has built Regeneron into a leading biotech with multiple FDA‑approved medicines and a deep in‑house science engine.
Company bio | Company LinkedIn | Company X
Reshma Kewalramani, M.D., FASN
Chief Executive Officer & President, Vertex Pharmaceuticals
Clinician‑executive who became CEO in 2020 and leads Vertex’s expansion beyond cystic fibrosis with multiple first‑in‑class programs.
Company bio | Company LinkedIn | Company X
Related Topics
Further Reading
Was this page helpful? We'd love your feedback — please email us at feedback@dealstream.com.